Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Symbiotec Pharmalab Ltd (SYMBIOTEC) is currently trading at 1,130.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Symbiotec Pharmalab Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Symbiotec Pharmalab Ltd has traded between a low of ₹933.80 and a high of ₹1,173.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Symbiotec Pharmalab Ltd has a market capitalization of approximately 7,030.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Symbiotec Pharmalab Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 60.96 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 7,030.58 Cr, Symbiotec Pharmalab Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Symbiotec Pharmalab Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Symbiotec Pharmalab Ltd is 60.96. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
721.00 | 7,711 Cr | 54.40 | 6.46 | 0.14 | 10.82 | 16.48 | 9.50 | ||
915.00 | 7,369 Cr | 37.15 | 6.15 | 0.11 | 17.46 | 23.00 | 14.62 | ||
1094.15 | 7,031 Cr | 60.96 | 5.41 | 0.00 | 9.56 | 11.55 | — | ||
1510.00 | 6,958 Cr | 53.18 | 7.45 | 0.00 | 12.36 | 14.43 | 8.16 | ||
1180.00 | 6,711 Cr | 43.57 | 6.15 | 0.17 | 12.92 | 14.30 | 8.38 | ||
202.05 | 6,596 Cr | 4.16 | 4.93 | 0.00 | 116.01 | 80.89 | 72.98 | ||
116.95 | 6,408 Cr | 45.58 | 5.14 | 0.17 | 5.96 | 7.58 | 7.26 | ||
| Median: 7 Co. | — | 915.00 | 6,958 Cr | 45.58 | 6.15 | 0.11 | 12.36 | 14.43 | 8.94 |
Bearish
0
Neutral
14
Bullish
0
Bearish
0
Neutral
42
Bullish
4
Bearish
0
Neutral
28
Bullish
4
Bearish
0
Neutral
14
Bullish
0
Bearish
0
Neutral
14
Bullish
0
Bearish
0
Neutral
28
Bullish
4
Bearish
0
Neutral
28
Bullish
4
Bearish
0
Neutral
28
Bullish
4
Pharmaceuticals & Biotechnology
Pharmaceuticals
7,031 Cr
Low Risk
61.0
37.7
1.8
5.4
1,173.80
933.80
Sales CAGR
Profit CAGR
ROE
ROCE
